UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 12, 2018
AEGLEA BIOTHERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
|
Delaware |
|
001-37722 |
|
46-4312787 |
|
(State or other jurisdiction of incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
|
901 S. MoPac Expressway Barton Oaks Plaza One Suite 250 Austin, TX |
78746 |
|
(Address of principal executive offices) |
(Zip Code) |
(512) 942-2935
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Item 7.01 Regulation FD Disclosure.
On April 12, 2018, Aeglea BioTherapeutics, Inc. issued a press release announcing new data from the Company’s Phase 1/2 clinical trial for the treatment of Arginase 1 Deficiency patients using pegzilarginase. A copy of the press release is attached as Exhibit 99.1 to this report.
The information furnished within this report, including Exhibit 99.1 to this report, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be incorporated by reference into any other filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
|
Exhibit Number |
|
Description |
|
|
|
|
|
99.1 |
|
Press release issued by Aeglea BioTherapeutics, Inc. on April 12, 2018 |
2
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
AEGLEA BIOTHERAPEUTICS, INC. |
||
|
|
|
|
|
|
|
|
|
Date: April 12, 2018 |
|
|
|
By: |
|
/s/ Charles N. York II |
|
|
|
|
|
|
|
Charles N. York II |
|
|
|
|
|
|
|
Chief Financial Officer |
3